MedTrace Logo

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

NCT06030843 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-08-07

No results posted yet for this study

Summary

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

Conditions

  • Empagliflozin in Cardiorenal Syndrome Type 1

Interventions

DRUG

Empagliflozin 10 MG

Empagliflozin 10 MG

DRUG

Placebo

Matching placebo containing Lactose content (0.26 gram)

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Nattachai Srisawat · Chulalongkorn University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-11-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06030843 on ClinicalTrials.gov